Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

SAN DIEGO -- Benefits with empagliflozin (Jardiance) for cardiovascular and renal health linger for about a year after discontinuation, as off-drug follow-up from the EMPA-KIDNEY trial showed. During ...

Adding an SGLT2 inhibitor to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction, an open-label randomized trial involving intensive care units ...

In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...

Observational study data suggest that SGLT2 inhibitor use reduces risks for kidney and cardiovascular events even in patients with an eGFR less than 15 mL/min/1.73 m2 who have type 2 diabetes.

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...